Edwards Lifesciences Corporation
EW · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,439,500 | $5,010,000 | $5,382,400 | $5,232,500 |
| % Growth | 8.6% | -6.9% | 2.9% | – |
| Cost of Goods Sold | $1,117,500 | $1,037,300 | $1,167,200 | $1,225,900 |
| Gross Profit | $4,322,000 | $3,972,700 | $4,215,200 | $4,006,600 |
| % Margin | 79.5% | 79.3% | 78.3% | 76.6% |
| R&D Expenses | $1,053,000 | $962,900 | $945,200 | $903,100 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,789,200 | $1,582,500 | $1,567,600 | $1,493,100 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $101,100 | $0 | $0 | $0 |
| Operating Expenses | $2,943,300 | $2,545,400 | $2,512,800 | $2,396,200 |
| Operating Income | $1,378,700 | $1,427,300 | $1,702,400 | $1,610,400 |
| % Margin | 25.3% | 28.5% | 31.6% | 30.8% |
| Other Income/Exp. Net | $169,400 | -$54,900 | $65,000 | $91,600 |
| Pre-Tax Income | $1,548,100 | $1,372,400 | $1,767,400 | $1,702,000 |
| Tax Expense | $152,100 | $152,400 | $245,500 | $198,900 |
| Net Income | $4,174,600 | $1,402,400 | $1,521,900 | $1,503,100 |
| % Margin | 76.7% | 28% | 28.3% | 28.7% |
| EPS | 6.98 | 2.31 | 2.46 | 2.41 |
| % Growth | 202.2% | -6.1% | 2.1% | – |
| EPS Diluted | 6.97 | 2.3 | 2.44 | 2.38 |
| Weighted Avg Shares Out | 597,700 | 606,700 | 619,000 | 623,300 |
| Weighted Avg Shares Out Dil | 599,300 | 609,400 | 624,200 | 631,200 |
| Supplemental Information | – | – | – | – |
| Interest Income | $120,300 | $67,200 | $35,500 | $17,400 |
| Interest Expense | $19,800 | $17,600 | $26,200 | $24,800 |
| Depreciation & Amortization | $155,200 | $144,900 | $166,800 | $163,300 |
| EBITDA | $1,723,100 | $1,534,900 | $1,960,400 | $1,890,100 |
| % Margin | 31.7% | 30.6% | 36.4% | 36.1% |